Navigation Links
HeartWare Schedules Fourth Quarter Conference Call and Webcast
Date:2/19/2013

FRAMINGHAM, Mass. and SYDNEY, Feb. 19, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2012, at 8:30 a.m. U.S. Eastern Standard Time on Wednesday, February 27, 2013. The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the fourth quarter and business outlook.  The call may be accessed by dialing 1-888-846-5003 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9856.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Fourth Quarter 2012 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's website, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, and has received CE Marking in the European Union and has been used to treat patients in 27 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Heartware Schedules First Quarter Conference Call And Webcast
3. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
4. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
5. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
6. HeartWare Names Peter F. McAree Chief Financial Officer
7. HeartWare Schedules Second Quarter Conference Call And Webcast
8. HeartWare Completes Acquisition Of World Heart Corporation
9. HeartWare Reports Second Quarter 2012 Results
10. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
11. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... WILLIAMSTON, Mich. , Feb. 21, 2017 /PRNewswire/ ... product innovation and global patient care, is making ... management with the launch of its IRIG-8™Wound ... system enables clinicians to quickly deliver copious volumes ... constant, effective pressure. This is a significant improvement ...
(Date:2/21/2017)... 21, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Muscle Spasticity ... and benchmarks in the global Muscle Spasticity market. The ... the key drugs marketed for Muscle Spasticity and their clinical attributes? ...
(Date:2/20/2017)... Taiwan Biophotonic Co. (tBPC), a medical device ... sensing solutions, today announced the CE Marking and the ... the oCare TM Pro 100, which is a quantum ... space.  tBPC,s Wrist Pulse Oximeter, the oCare ... reliable method to measure and record heart rate and ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... VA (PRWEB) , ... February 20, 2017 , ... Silverado ... Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, Virginia. ... 2018 on a site just outside of Old Town. , The three-story community ...
(Date:2/20/2017)... ... February 20, 2017 , ... Clearwave is the ... on the Posiflex XT-series of touch screen terminals. Both companies will be showcasing ... Florida. The terminal provider Posiflex is helping to bridge the gap between healthcare ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... as an employee health benefit for companies that want to help members of ... providers, employees will have access to Watson’s suite of oncology offerings for insights ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and ... Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, New York ... needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s in a ...
Breaking Medicine News(10 mins):